Create a Free Profile
Tell us about you: what you’re living with, what you’ve tried and what you’re exploring.
CAR-T Cell Therapy When Lymphoma, Leukemia or Myeloma Comes Back
Your own immune cells, reprogrammed to find and fight disease, then returned to you in a single infusion. Find the practices that offer it and choose the ones you want to talk to.
Approved for Some Uses
Several CAR-T therapies are FDA-approved for certain blood cancers. Armored, off-the-shelf and autoimmune uses are investigational.
Free to join. No card required.
What Is CAR-T?
CAR-T starts with collecting your T cells, a type of white blood cell, from your blood. In a lab, they are given a new receptor, the CAR, that lets them recognize a marker on cancer cells. The cells are multiplied and infused back into you, where they seek out and destroy their target.
Two newer forms are in clinical trials. Armored CAR-T cells carry extra features that help them survive and keep working in a hostile environment, such as a solid tumor. Off-the-shelf, or allogeneic, CAR-T is made in advance from donor cells, so treatment does not wait for your own cells to be manufactured.
Conditions It’s Used or Studied For
Lymphoma
Leukemia
Multiple Myeloma
Lupus and Autoimmune Disease (In Trials)
Solid Tumors (In Trials)
Only your physician can say whether it is right for you.
Before You Match
What to Know
-
Approved Uses Are Specific
FDA-approved CAR-T is for certain blood cancers, often after other treatment. Ask whether your diagnosis and history fit.
-
It Is Given at Specialized Centers
Treatment and close monitoring happen at centers equipped for it, and you will need to stay nearby for at least the first two weeks.
-
Side Effects Are Watched Closely
Cytokine release syndrome and neurological effects are known risks. Ask how the team monitors and treats them.
-
Newer Versions Mean Trials
Armored, off-the-shelf and autoimmune CAR-T are investigational. Eligibility is set by each study.
More About CAR-T
Health e Match summarized this information from the sources listed below. It is general information, not medical advice.
Who Is a Candidate?
FDA-approved CAR-T therapies treat specific blood cancers: certain B-cell lymphomas, B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. Most approvals are for cancer that has come back or not responded after one or more earlier treatments.
Candidates generally need adequate heart, lung and kidney function and a caregiver who can stay with them after treatment. Trials are testing CAR-T for lupus and other autoimmune diseases, for solid tumors, and in armored and off-the-shelf forms, each with its own criteria.
What to Expect
Treatment with your own cells happens in stages. First, white blood cells are collected in a process similar to donating plasma (leukapheresis), which takes a few hours. The cells are then engineered and grown in a lab over several weeks; some people receive bridging treatment to control the cancer while they wait.
A few days of low-dose chemotherapy prepare the body, and the CAR-T cells are then given as an infusion that often takes less than an hour. Off-the-shelf CAR-T, being studied in trials, skips the collection and manufacturing wait.
Recovery and Follow-Up
The first weeks after infusion carry the highest risk of side effects, so patients are monitored closely, sometimes in the hospital. Since June 2025, labeling for approved products asks patients to stay near the treatment center for about two weeks after infusion and not to drive for two weeks.
Blood counts can take weeks to months to recover. Long-term follow-up includes checking for infections, antibody levels and how the cancer is responding.
Risks and Side Effects
The two best-known risks are cytokine release syndrome, which can cause fever, low blood pressure and trouble breathing, and neurological effects that can cause confusion, difficulty speaking or seizures. Both are usually treatable when caught early, which is why monitoring is so close.
Other risks include low blood counts, serious infections and low antibody levels. Approved CAR-T products also carry a warning about rare secondary cancers of the T cells.
Cost and Insurance
Approved CAR-T is among the most expensive treatments in medicine, and it nearly always requires prior authorization. Medicare and most private insurers cover it for approved uses.
Ask the treatment center about out-of-pocket costs, whether it helps with travel and lodging during the weeks you must stay nearby, and about manufacturer patient-support programs. In trials, the investigational cells are usually provided at no cost.
Choosing a Practice
Questions worth asking in your first conversation:
- Is the center authorized to give the specific CAR-T product for my diagnosis?
- How many CAR-T patients does the team treat, and how does it manage side effects?
- Will I be treated as an inpatient or outpatient, and where will I stay?
- Are there armored, off-the-shelf or autoimmune trials I might qualify for?
Alternatives to Consider
Depending on the cancer, alternatives include bispecific antibodies (approved for some lymphomas and for multiple myeloma), stem cell transplant, further chemotherapy or targeted therapy, and other clinical trials. Your oncologist can explain where CAR-T fits in your treatment sequence.
Sources
Find a Practice That Offers It
Searching for CAR-T usually means a long list of names and no way to tell who actually offers it. Here, you meet verified practices that treat what you listed, and you decide who to talk to.
We’ll Introduce You
We only introduce verified practices that treat what you listed.
Choose Each Other
Swipe on the ones you like. When they swipe back — it’s a match!
Free to join. No card required.
Questions
What Patients Ask
Is CAR-T FDA-approved?
Yes, several CAR-T therapies are FDA-approved for specific blood cancers, including certain lymphomas, leukemias and multiple myeloma. Uses outside those approvals, including lupus and other autoimmune diseases, are investigational.
What is armored CAR-T?
CAR-T cells engineered with additional features, such as releasing their own immune-boosting signals, so they can keep working where ordinary CAR-T cells struggle. It is investigational.
What does off-the-shelf mean?
The cells come from healthy donors and are prepared in advance, rather than made from your own cells after you are referred. It is investigational.
How do I find a practice that offers CAR-T?
Build a free profile, list your diagnosis and that you are exploring CAR-T, and you will meet practices that treat what you listed. Swipe on the ones you like. When they swipe back, it’s a match.
Start Matching Today
Build a free profile in minutes. List what you’re living with and that you’re exploring CAR-T, and meet the practices that treat it.
Free to join. No card required.
This page is general information, not medical advice, and it was last updated October 15, 2026. healthematch.com makes introductions between patients and practices in the United States. It does not provide medical care, does not enroll anyone in clinical research, and does not recommend any particular procedure or provider. Where a practice has documented a therapy’s regulatory status, it is shown exactly as documented. Are you a practice? See the CAR-T page for practices.